Mark S. Graham

Array ( [id] => 9408050 [patent_doc_number] => 20140099302 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-10 [patent_title] => 'METHODS TO IDENTIFY RESPONSIVE PATIENTS' [patent_app_type] => utility [patent_app_number] => 14/046913 [patent_app_country] => US [patent_app_date] => 2013-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 12513 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14046913 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9280295 [patent_doc_number] => 20140030263 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-01-30 [patent_title] => 'TREATMENT OF DIFFUSE LARGE-CELL LYMPHOMA WITH ANTI-CD20 ANTIBODY' [patent_app_type] => utility [patent_app_number] => 14/045375 [patent_app_country] => US [patent_app_date] => 2013-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4169 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14045375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11356403 [patent_doc_number] => 09533043 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-03 [patent_title] => 'Identification of surface-associated antigens for tumor diagnosis and therapy' [patent_app_type] => utility [patent_app_number] => 14/036969 [patent_app_country] => US [patent_app_date] => 2013-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 66 [patent_no_of_words] => 31547 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14036969 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10347567 [patent_doc_number] => 20150232572 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-20 [patent_title] => 'COMBINATION TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 14/425158 [patent_app_country] => US [patent_app_date] => 2013-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 22359 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14425158 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11249287 [patent_doc_number] => 09474771 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-10-25 [patent_title] => 'Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase' [patent_app_type] => utility [patent_app_number] => 14/012172 [patent_app_country] => US [patent_app_date] => 2013-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 38 [patent_no_of_words] => 22332 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14012172 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9294058 [patent_doc_number] => 20140037692 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-06 [patent_title] => 'ANTITUMOR VACCINATION USING ALLOGENEIC TUMOR CELLS EXPRESSING ALPHA (1,3)-GALACTOSYLTRANSFERASE' [patent_app_type] => utility [patent_app_number] => 13/966446 [patent_app_country] => US [patent_app_date] => 2013-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 21471 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13966446 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11697671 [patent_doc_number] => 09687568 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-06-27 [patent_title] => 'Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label' [patent_app_type] => utility [patent_app_number] => 13/961167 [patent_app_country] => US [patent_app_date] => 2013-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 10 [patent_no_of_words] => 14362 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13961167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10318585 [patent_doc_number] => 20150203588 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-23 [patent_title] => 'Cancer Biomarkers and Methods of Use Thereof' [patent_app_type] => utility [patent_app_number] => 14/416502 [patent_app_country] => US [patent_app_date] => 2013-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 10111 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14416502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10312569 [patent_doc_number] => 20150197571 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-16 [patent_title] => 'Single Agent Anti-PD-L1 and PD-L2 Dual Binding Antibodies and Methods of Use' [patent_app_type] => utility [patent_app_number] => 14/418536 [patent_app_country] => US [patent_app_date] => 2013-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45175 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 15 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14418536 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9634335 [patent_doc_number] => 20140212443 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-31 [patent_title] => 'IMMUNITY TO FOLATE RECEPTORS' [patent_app_type] => utility [patent_app_number] => 13/917410 [patent_app_country] => US [patent_app_date] => 2013-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 9988 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13917410 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10566368 [patent_doc_number] => 09289519 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-22 [patent_title] => 'Alpha emitting constructs and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/897798 [patent_app_country] => US [patent_app_date] => 2013-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 11 [patent_no_of_words] => 12927 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13897798 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9222391 [patent_doc_number] => 20140017166 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-01-16 [patent_title] => 'MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES' [patent_app_type] => utility [patent_app_number] => 13/870796 [patent_app_country] => US [patent_app_date] => 2013-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 43186 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13870796 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9093743 [patent_doc_number] => 20130273054 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-17 [patent_title] => 'Bispecific Anti ErbB2/Anti cMet Antibodies' [patent_app_type] => utility [patent_app_number] => 13/860353 [patent_app_country] => US [patent_app_date] => 2013-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 26826 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13860353 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8989280 [patent_doc_number] => 20130216561 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-22 [patent_title] => 'Immunoconjugates with an Intracellularly-Cleavable Linkage' [patent_app_type] => utility [patent_app_number] => 13/845694 [patent_app_country] => US [patent_app_date] => 2013-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11312 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13845694 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8976029 [patent_doc_number] => 20130209459 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-15 [patent_title] => 'TREATMENT WITH ANTI-ErbB2 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 13/841146 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 17530 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13841146 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11356392 [patent_doc_number] => 09533031 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-03 [patent_title] => 'Yeast-MUC1 immunotherapeutic compositions and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/803757 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 7 [patent_no_of_words] => 38046 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13803757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11612590 [patent_doc_number] => 09650440 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-05-16 [patent_title] => 'Monoclonal antibodies that specifically block biological activity of a tumor antigen' [patent_app_type] => utility [patent_app_number] => 13/826964 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 6 [patent_no_of_words] => 19037 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13826964 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9041135 [patent_doc_number] => 20130243773 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-09-19 [patent_title] => 'RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 13/795637 [patent_app_country] => US [patent_app_date] => 2013-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 33983 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13795637 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8883588 [patent_doc_number] => 20130156772 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-20 [patent_title] => 'Bispecific Anti ErbB1 / Anti cMet Antibodies' [patent_app_type] => utility [patent_app_number] => 13/774192 [patent_app_country] => US [patent_app_date] => 2013-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 26941 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13774192 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10588769 [patent_doc_number] => 09310377 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-04-12 [patent_title] => 'High affinity binding site of HGFR and methods for identification of antagonists thereof' [patent_app_type] => utility [patent_app_number] => 13/773497 [patent_app_country] => US [patent_app_date] => 2013-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 9519 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 202 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13773497 [rel_patent_id] =>[rel_patent_doc_number] =>)